A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer

類似資料

• Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial()
  著者:: Eustace, Amanda, 等
  出版事項: (2013)
• Expression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer
  著者:: Irlam-Jones, J J, 等
  出版事項: (2016)
• Expression of hypoxia-inducible factor-1α predicts benefit from hypoxia modification in invasive bladder cancer
  著者:: Hunter, B A, 等
  出版事項: (2014)
• Exon Array Analysis of Head and Neck Cancers Identifies a Hypoxia Related Splice Variant of LAMA3 Associated with a Poor Prognosis
  著者:: Moller-Levet, Carla S., 等
  出版事項: (2009)
• Correction: Validation of a hypoxia related gene signature in multiple soft tissue sarcoma cohorts
  著者:: Yang, Lingjian, 等
  出版事項: (2019)